Withum’s Columbia Office Welcomes Greater Baltimore

By Whitney Irish

Withum team members, clients and community leaders, including representatives from Howard County and the Central Maryland Chamber, came together to mark the official “door opening” on the new location. The ribbon-cutting ceremony highlighted the evening, which featured citations presented by community leaders welcoming Withum to the Columbia region and recognizing its strong ties to the…

Why Intangible Value Dominates in Digital Health: A CFO’s Guide

By Allison Katz

For health system and digital health leaders, enterprise value is often assessed through familiar financial lenses, such as revenue growth, EBITDA margins, and scale potential. These metrics remain important. However, in digital health, they rarely explain why value persists, where risk accumulates, or how short-term performance translates into long-term enterprise value. This disconnect exists because…

The Importance of Separating Business and Personal Expenses

By Allison Katz

Few financial disciplines separate well-run businesses from struggling ones as clearly as a clean boundary between business and personal expenses. It is easy to dismiss this practice as administrative housekeeping. In reality, the failure to keep the two separate quietly undermines nearly every financial decision an owner makes. When business and personal spending are commingled,…

Accounting for Real Estate Held for Sale

By Allison Katz

Real estate professionals and investors will inevitably encounter situations where selling a property becomes necessary. The classification and accounting treatment can significantly impact their financial statements. ASC 360, under US GAAP, requires that long-lived assets be classified as held for sale in the period in which all of the held-for-sale criteria are met. Once all…

Maximizing Innovation Incentives: How the Orphan Drug Credit Can Outperform the R&D Tax Credit

By Allison Katz

The Orphan Drug Credit (ODC) is a powerful federal tax incentive designed to encourage the development of treatments for rare diseases, generally defined as conditions affecting fewer than 200,000 individuals in the United States. For biotechnology and pharmaceutical companies advancing therapies through clinical trials, the ODC can deliver a significantly enhanced tax benefit compared to…

A Practical Look at the DOL’s Proposed Rule on Selecting Investment Options

By Allison Katz

On March 31, 2026, the Department of Labor (DOL) issued a proposed rule specific to 401k plans on “Fiduciary Duties in Selecting Designated Investment Alternatives.” This comes at a time when alternative investments are becoming more widespread. While alternative investments may have triggered this proposed ruling, the more important takeaway is how the DOL is…